CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
entinostat +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01105377
NCT01105377Phase 2Completed
CompareCT.gov

Phase II Study of Azacitadine and Entinostat in Patients With Metastatic Colorectal Cancer

National Cancer Institute (NCI)·interventional·Posted Apr 16, 2010·Updated Aug 1, 2014

In Brief

A Phase 2 clinical trial evaluating entinostat, azacitidine, and 1 other intervention for Recurrent Colon Cancer and 3 related conditions. Completed, enrolled 47 participants across 14 sites.

Detailed Summary

This phase II trial is studying how well giving azacitidine together with entinostat works in treating patients with metastatic colorectal cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving azacitidine together with entinostat may kill more tumor cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 16, 2010
Enrollment StartApr 1, 2010
Primary CompletionMar 1, 2012
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 16.2 years ago

Interventions

entinostatdrug

Given orally

azacitidinedrug

Given SC

laboratory biomarker analysisother

Correlative studies